timothy sykes logo

Stock News

Nektar Therapeutics Soars Amidst Sanofi’s Setback

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
Updated 9/18/2025, 5:06 pm ET 9/18/2025, 5:06 pm ET | 6 min 6 min read
Nektar Therapeutics Soars Amidst Sanofi’s Setback Thumbnail

Nektar Therapeutics’ stocks have been trading up by 17.04 percent following promising developments in their novel therapeutic pipeline.

  • The strong candidate REZPEG showcased promising results in Phase 2b, highlighting its potential in the competitive atopic dermatitis market. Piper Sandler expressed a bullish outlook, citing REZPEG’s appealing commercial potential.

  • Investors expressed renewed interest following Sanofi’s underwhelming drug performance, creating positive momentum for Nektar’s stock.

  • Nektar is preparing to share further insights at upcoming investment conferences, elevating confidence and interest around its innovative dermatological solutions.

Candlestick Chart

Live Update At 17:05:15 EST: On Thursday, September 18, 2025 Nektar Therapeutics stock [NASDAQ: NKTR] is trending up by 17.04%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Performance and Earnings Overview

In the fast-paced world of trading, it’s crucial to maintain discipline and avoid impulsive decisions. As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.” This advice is imperative for traders seeking success. Rushing into trades without proper analysis and market conditions can lead to unnecessary losses. Instead, traders should focus on perfecting their strategies and waiting for the right opportunities to present themselves. By doing so, they can maximize their potential for profits and minimize their risks.

Nektar Therapeutics reported a shift in its financial performance, drawing both attention and criticism. The company has observed fluctuations in its revenue streams, demonstrating intriguing, yet challenging dynamics. The revenue has steadily decreased by 8.03% over three years and 14.34% over five years. Despite these drops, the company’s gross margins are impressive at 83.4%, indicating strong control over production costs relative to its sales.

The income statement reveals a net income of -$41.59M, reflecting substantial investment but also signifying struggles in profitability. Notably, operating expenses stood at $46.96M, underlining the high cost of advancing clinical trials and technological development. Their basic earnings per share (EPS) dipped to -2.95, showcasing deferred returns to shareholders during strategic expansions.

Analyzing balance sheets, total assets tallied $207.53M, with liabilities surpassing equity due to continuing investment obligations. The delicate dance between asset acquisition and liabilities reflects Nektar’s ambitious growth prospects in pursuing innovation.

Cash flow analysis highlights an operation-centric investment approach. Operating cash flow indicates a cash consumption of -$45.73M, suggesting high operating turnover. Correspondingly, positive cash flow from investing activities netted $49.61M, owing to strategic acquisitions and sale of short-term investments worth $68.57M. It’s clear there is a concentration on long-term capital appreciation over immediate returns.

Key ratios indicate areas requiring improvement, particularly in profitability (negative EBIT and EBITDA margins) yet reflect strong asset management with receivables turnover at 125.3. It’s evident that Nektar remains well-positioned for reverse-breaking performance but demands patience due to significant internal financial adjustments.

Overall, while Nektar faces formidable challenges, its bold strides in innovation promise future profitability. Investor sentiment echoes optimism around its robust pipeline and advancing technologies in dermatology.

Reasons Behind the Stock Surge

The drastic change in Nektar Therapeutics’ stock can be attributed to a multitude of factors that emphasize the company’s forward movement amidst industry uncertainties.

As Sanofi’s anticipated drug faltered in the late-stage trials, market favor pivoted towards Nektar’s pioneering alternative, REZPEG. This candidate not only holds remarkable potential but also safeguards continued trader enthusiasm, reaffirmed by positive Phase 2b outcomes.

Echoing this sentiment, Piper Sandler emphasized Nektar’s strategic opportunity to carve a competitive edge in the dermatological drug sphere. The lackluster performance from Sanofi further galvanized support for Nektar, fortifying its market prominence and stirring aggressive buying behaviors.

The ensuing fervor isn’t just confined to insiders and analysts. Public markets responded robustly, as witnessed through increased share volumes and heightened demand for Nektar’s stock. This newly inked trajectory reaffirms the efficacy of having diverse candidates and innovation portfolios, which can be pivotal given industry vicissitudes.

Traders eagerly await September conferences, poised to learn about groundbreaking products and financial strategies from company forums. Nektar’s willingness to engage with stakeholders through transparent dialogues suggests a budding focus on inspiring domain confidence. The evolving market landscape hints at potential partnerships and acquisitions, feeding into larger narratives of long-term sustainability and growth ambition.

The company, benefiting from advantageous timing, is tactfully leveraging its innovative prowess amidst competitors’ setbacks. Nektar continues strengthening its footing in the pharma realm, illustrating its readiness to seize unparalleled market openings. In line with prudent trading principles, as millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.”

In conclusion, Nektar Therapeutics finds itself at a conspicuous crossroads, its ambition illuminated by compelling triumphs and market reception. But such ambition necessitates both robust innovation and transparency. Traders are decisively optimistic, as they witness a compelling drug prospect unravel amid turbulent industry currents. Still, remembering that volatility entails risk remains crucial as the company navigates its impending future.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”